Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors.


Por: Fuentes-Fayos AC, García-Martínez A, Herrera-Martínez AD, Jiménez-Vacas JM, Vázquez-Borrego MC, Castaño JP, Picó A, Gahete MD and Luque RM

Publicada: 1 jun 2019 Ahead of Print: 16 ene 2019
Resumen:
Acromegaly is a chronic systemic disease mainly caused by a growth hormone (GH)-secreting pituitary neuroendocrine tumor (PitNETs), which is associated with many health complications and increased mortality when not adequately treated. Transsphenoidal surgery is considered the treatment of choice in GH-secreting PitNETs, but patients in whom surgery cannot be considered or with persistent disease after surgery require medical therapy. Treatment with available synthetic somatostatin analogues (SSAs) is considered the mainstay in the medical management of acromegaly which exert their beneficial effects through the binding to a family of G-protein coupled receptors encoded by 5 genes (SSTR1-5). However, although it has been demonstrated that the SST1-5 receptors are physically present in tumor cells, SSAs are in many cases ineffective (i.e. approximately 10-30% of patients with GH-secreting PitNET are unresponsive to SSAs), suggesting that other cellular/molecular determinants could be essential for the response to the pharmacological treatment in patients with GH-secreting PitNETs. Therefore, the scrutiny of these determinants might be used for the identification of subgroups of patients in whom an appropriate pharmacological treatment can be successfully employed (responders vs. non-responders). In this review, we will describe some of the existing, classical and novel, genetic and molecular determinants involved in the response of patients with GH-secreting PitNETs to the available therapeutic treatments, as well as new molecular/therapeutic approaches that could be potentially useful for the treatment of GH-secreting PitNETs.

Filiaciones:
Fuentes-Fayos AC:
 Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain

 Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain

 Reina Sofia University Hospital (HURS), Cordoba, Spain

 CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Cordoba, Spain

:
 Research Laboratory, Hospital General Universitario de Alicante-Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain

Herrera-Martínez AD:
 Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain

 Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain

 Reina Sofia University Hospital (HURS), Cordoba, Spain

 CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Cordoba, Spain

Jiménez-Vacas JM:
 Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain

 Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain

 Reina Sofia University Hospital (HURS), Cordoba, Spain

 CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Cordoba, Spain

Vázquez-Borrego MC:
 Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain

 Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain

 Reina Sofia University Hospital (HURS), Cordoba, Spain

 CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Cordoba, Spain

Castaño JP:
 Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain

 Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain

 Reina Sofia University Hospital (HURS), Cordoba, Spain

 CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Cordoba, Spain

:
 Department of Endocrinology and Nutrition, Hospital General Universitario de Alicante-ISABIAL, Miguel Hernández University, CIBERER, Alicante, Spain

Gahete MD:
 Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain

 Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain

 Reina Sofia University Hospital (HURS), Cordoba, Spain

 CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Cordoba, Spain

Luque RM:
 Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain -

 Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain

 Reina Sofia University Hospital (HURS), Cordoba, Spain

 CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Cordoba, Spain
ISSN: 03911977





Minerva endocrinologica
Editorial
Edizioni Minerva Medica, CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY, Italia
Tipo de documento: Article
Volumen: 44 Número: 2
Páginas: 109-128
WOS Id: 000474741200002
ID de PubMed: 30650942

MÉTRICAS